Can CVS Health Buy BioPharmX Corporation?

May 24, 2018 / by CWEB

Can CVS Health Buy BioPharmX Corporation? – CWEB.com

- Corporate health-care deal value surged 37 percent last year, according to a new report from consulting firm Bain & Company.
- The number of health-care mergers and acquisitions rose 16 percent.
- CVS Health's planned acquisition of health insurer Aetna was the largest corporate deal of 2017 at $69 billion.

The health-care shopping spree isn't likely to stop anytime soon.

Corporate deal value surged to $332 billion last year, up 27 percent from $261 billion in 2016, though still below the peak of $432 billion in 2015, according to a new report from consulting firm Bain & Company.

What does make BioPharmX unique?

1. **Financial Health**: Does it have a healthy balance sheet?
2. **Management**:Have insiders been ramping up their shares to take advantage of the market's sentiment for BPMX's future outlook?
3. **Other High-Growth Alternatives**: BPMX is a high-growth stock you could be holding?

Walgreens was also reportedly considering acquiring the part of drug distributor AmerisourceBergen that it doesn't already own earlier this year, though talks have cooled. Walmart and health insurer Humana are having early-stage talks about strengthening their existing partnership, people familiar with the matter told CNBC.

BioPharmX Corporation (BPMX) products are sold in CVS Health Pharmacy (NYSE:CVS),

Walgreens, Drugstore.com, GNC (NYSE:GNC), The Vitamin Shoppe, Harris Teeter and many more.

BioPharmX added 3,025 GNC store locations supplying Violet® iodine, raising its
U.S. retail footprint to more than 7,500 stores. Availability of Violet iodine at GNC is expected to begin in
mid-December. GNC is a leading global specialty retailer of health and wellness products and is devoted to helping its
customers improve the quality of their lives. We believe the addition of GNC stores will accelerate VI2OLET revenue growth in the coming quarters.

Institutional investors currently hold major shares in BioPharmX Corporation(BPMX) stock. Majority of the recent share have been purchased by Vanguard Investment firm on 5-13-2018

OWNER NAME	DATE	SHARED HELD	CHANGE (SHARES)	CHANGE (%)	VALUE (IN 1,000S)
VIVO CAPITAL, LLC	05/13/2018	16,128,515	2,328,571	16.87	3,306
FRANKLIN RESOURCES INC	05/13/2018	9,749,615	0	0.00	1,999
VANGUARD GROUP INC	05/13/2018	5,498,918	3,541,971	181.00	1,127
GEODE CAPITAL MANAGEMENT, LLC	03/31/2018	671,686	347,719	107.33	138
VIRTU FINANCIAL LLC	03/31/2018	426,837	426,837	New	88

BARCLAYS PLC	03/31/2018	362,900	362,900	New	74
SUSQUEHANNA INTERNATIONAL GROUP, LLP	03/31/2018	181,335	181,335	New	37
CITADEL ADVISORS LLC	03/31/2018	146,859	146,859	New	30
MCF ADVISORS LLC	03/31/2018	105,629	105,629	New	22
JANE STREET GROUP, LLC	03/31/2018	96,941	96,941	New	20
TWO SIGMA SECURITIES, LLC	03/31/2018	93,390	47,105	101.77	19
NORTHERN TRUST CORP	03/31/2018	92,518	0	0.00	19
UBS GROUP AG	03/31/2018	70,367	36,614	108.48	14
LADENBURG THALMANN FINANCIAL SERVICES INC.	03/31/2018	64,200	0	0.00	13
CREDIT SUISSE AG/	03/31/2018	50,000	50,000	New	10

	HOLDERS	SHARES
Increased Positions	17	7,708,826
Held Positions	7	15,447,095
Total Institutional Shares	27	33,878,519

Institutional Ownership

Institutions own approximately 19.42% of BioPharmX' shares. Among active positions in the latest quarter, 7 holders increased their positions by a total of 10.8 million shares. This means there is a net increase in ownership of 9.61 million shares, which may suggest that institutions feel bullish about the stock.

Cash as of March 9, 2018

- Pro-forma cash of $14.2 million
  - $8.6 million as of January 31, 2018
  - $6.7 million in proceeds from warrant exercises after the end of the quarter

Reverse Split

The company let an already approved reverse split expire.

> ***"Regarding the expired reverse stock split, the company and its shareholders did not feel such an action would be in the best interest of the shareholders once the company was able to bring the company back into compliance with the NYSE American's continued listing standards. The company is optimistic that it will be in compliance for continued listing standards regarding its share price by the June deadline."***

Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators also suggest that BioPharmX Corporation (BPMX) , is undervalued.

A potential Buy is very possible for **BioPharmX Corporation by a major Drug chain like CVS or Walgreens Pharmacy.**

CWEB Analysts have Reiterate a Buy Rating for BioPharmX Corporation (BPMX) and a Price Target of $7 within 12 months.

Like this:

Like

Be the first to like this.

Related

Why Did The Vanguard Group Inc. Increased Its Shares To Almost $6 Million In BPMX
May 20, 2018
Similar post

Why BiopharmX Corp Is A Good Buy
May 18, 2018
Similar post

Don't Buy Etsy (NASDQ : Etsy) Citi Issues A Warning - CWEB.com
May 30, 2017
In "CWEB Business News"

Comment

LEAVE A REPLY

Enter your comment here...